Poems

Deep vein thrombosis associated with central venous catheters a review

Categories
Published
of 11
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Related Documents
Share
Description
Journal of Thrombosis and Haemostasis, 3: REVIEW ARTICLE Deep vein thrombosis associated with central venous catheters a review C. J. VAN ROODEN,* M. E. T. TESSELAAR, S. OSANTO, F. R. ROSENDAALà
Transcript
Journal of Thrombosis and Haemostasis, 3: REVIEW ARTICLE Deep vein thrombosis associated with central venous catheters a review C. J. VAN ROODEN,* M. E. T. TESSELAAR, S. OSANTO, F. R. ROSENDAALà and M. V. HUISMAN* Departments of *General Internal Medicine, Clinical Oncology, àclinical Epidemiology and Hematology, Leiden University Medical Center, Leiden, The Netherlands To cite this article: van Rooden CJ, Tesselaar MET, Osanto S, Rosendaal FR, Huisman MV. Deep vein thrombosis associated with central venous catheters a review. J Thromb Haemost 2005; 3: Introduction Central venous catheters (CVCs) are frequently used in patients for a variety of indications such as cancer treatment, diagnostic monitoring, parenteral nutrition, hemodialysis, cardiac pacing, and administration of fluids, blood products or medication [1]. The benefit derived from a CVC may be offset by thrombosis and associated complications, such as pulmonary embolism (PE), CVC dysfunction, infection or loss of central venous access. In the long term patients with thrombosis may suffer from a post-thrombotic syndrome [1,2]. The CVC-related thrombosis is an issue of importance to many clinicians, and insight into the different aspects is crucial to guide decisions in treatment in often vulnerable patients in daily practice. In medical literature, there is a lack of uniformity and uncertainty about several entities of CVCrelated thrombosis. First, two types of CVC-related thrombosis must be clearly distinguished; i.e. clinically manifest and subclinical thrombosis. Furthermore, the type of thrombosis and the incidence is defined by the diagnostic strategy in patients with a CVC. Anticipation of the risk of CVC-related thrombosis and the identification of certain Ôhigh-riskÕ patients who are prone to develop thrombosis and secondary complications, is essential to initiate early preventive measurements such as prophylactic anticoagulation. The need for anticoagulant prophylaxis is however still a subject of discussion [3,4]. Finally, for the treatment of established CVC-related thrombosis, several therapeutic options were evaluated in literature. General recommendations of anticoagulant treatment, and whether CVC removal is necessary or not, is warranted. The primary aim of this review is to describe the diagnostic methods and their performance, the incidence and risk factors, Correspondence: Menno V. Huisman, Department of General Internal Medicine, Leiden University Medical Center, PO box 9600, 2300 RC Leiden, The Netherlands. Tel.: +31(0) ; fax: +31(0) ; lumc.nl Received 15 July 2004, accepted 28 February 2005 complications, prevention and treatment of CVC-related thrombosis from a practical clinical point of view. English medical literature studies were retrieved by an extensive Medline search (Pubmed Ò ) and bibliographies of the obtained studies were crosschecked where necessary. For each subject, only those studies with the strongest level of evidence, as defined and discussed in the subsequent paragraphs, were selected and reviewed. Diagnosis of CVC-related thrombosis In view of diagnosis of CVC-related thrombosis, two types of thrombosis can be distinguished; clinically manifest thrombosis and subclinical thrombosis. Clinically manifest thrombosis is defined as thrombosis objectified by diagnostic imaging (ultrasound, venography) upon overt symptoms and signs, such as pain or tenderness, warmth, swelling or edema, bluish discoloration or visible collateral circulation. Subclinical thrombosis, defined as thrombosis in the absence of signs and symptoms, is demonstrated by screening diagnostic imaging. Most thrombotic events associated with CVCs remain subclinical, or complications such as PE are the first presenting symptom [5 7]. Radiologically, thrombosis can have a typical appearance of enveloping sleeve surrounding the CVC (Fig. 1) or be characterized by mural thrombosis adherent to the venous vessel wall [8]. Mural thrombosis, present in approximately 30% of patients with CVCs, may cause subtotal stenosis (Fig. 2) or occlusion of the venous lumen and lead to clinically manifest thrombosis or associated complications [6]. Mural thrombosis is often found near the entry site of the CVC into the vessel or at the junction of large veins, although it may be extended or located into adjacent venous segments or the right atrium. In the diagnostic work-up of CVC-related thrombosis, diagnostic imaging upon a clinical suspicion of thrombosis is mandatory. A diagnosis based solely on clinical symptoms and signs of thrombosis is non-specific, as in deep vein thrombosis (DVT) of the leg. In only about a third to a half of all patients in whom thrombosis is clinically suspected, the diagnosis is confirmed [9 11]. 2410 C. J. van Rooden et al Fig. 1. Ultrasonic appearance of a typical enveloping Ôfibrin sheathõ demonstrated immediately after central venous catheter removal (Jugular vein). Fig. 2. Nearly occlusive mural thrombosis visualized by a flow defect, detected by Color Doppler Flow Imaging, just after central venous catheter removal. Contrast venography is widely recognized as the reference standard in the diagnosis of thrombosis [12]. However, ultrasound is most often used clinically, because it is noninvasive, does not expose to ionizing radiation, can easily be performed at the bedside and is well accepted by patients. In modern ultrasonography, real time gray-scale images (B-mode) are obtained and the criteria of non-compressibility (compression ultrasound) and direct visualization of thrombotic material in the venous lumen can be used to establish the presence or absence of thrombosis. Besides, real time changes in vessel diameter due to respiration may detect occlusive thrombosis more centrally located. In addition, Doppler techniques can add the advantage of evaluation of blood-flow. With pulsed Doppler signals added to gray scale imaging (Duplex ultrasound) qualitative and quantitative information of blood flow can be obtained. Color Doppler Flow Imaging (CDFI) displays blood flow in color in addition to gray scale imaging. A combination of all three modalities is called color duplex ultrasound. In symptomatic lower extremity DVT, compression ultrasonography has been validated in clinical practice [13], but specifically for thrombosis associated with femorally inserted CVCs, no studies are available in which ultrasound was compared with venography. With regard to the upperextremity DVT, venography has high to moderate interobserver agreement rates (71% 83%) and can be used as a reference test in clinical practice [14]. In several studies the diagnostic accuracy of ultrasound in upper extremity thrombosis compared with venography was evaluated. For the purpose of this review, we selected those studies in which ultrasound was compared with routine contrast venography in the diagnosis of upper-extremity DVT in the entire cohort of reported patients, and which results were independently interpreted by blinded observers. Overall, six studies were retrieved (Table 1) in which patients with CVCs were included. The reported sensitivity of ultrasound in the diagnosis of upper extremity DVT among these studies ranged from 56% to 100%, whereas the specificity ranged from 77% to 100% [10,11,15 18]. Reports specifically aimed at patients with CVCs are limited to three studies only [16 18], Importantly, in patients with CVC-related thrombosis, thrombosis tends to be located more centrally than in patients with thrombosis not related to CVCs [4]. As a consequence, the diagnostic technique of ultrasound, and therefore the accuracy, in patients with suspected thrombosis because of CVCs is different than those without (history of) CVC. In one study continuous wave Doppler without gray scale imaging only was used, a technique hardly applied nowadays [18]. Applying modern techniques, Duplex ultrasound was reported to have an excellent specificity (100%), however the sensitivity was substantially lower (56%) [17]. In another study, CDFI was found to be more sensitive (sensitivity 94% specificity 96%) [16]. Summary In summary, reliable data on the accuracy of ultrasound in CVC-related thrombosis are limited. In lower extremity CVC-related thrombosis no studies are available. In upper extremity CVC-related thrombosis specifically, only three studies are available, of which CDFI had the best performance (sensitivity 94%, specificity 96%). In view of the advantages of ultrasound mentioned, and the high specificity, patients with clinically suspected CVC-related thrombosis, should undergo ultrasound initially. However, the safety of withholding treatment in case of a negative ultrasound in patients suspected for thrombosis is uncertain [19]. As a consequence, in patients with normal ultrasound additional venography could be performed. Alternative strategies such as serially performed ultrasound, spiral CT or MRI may be useful and of potential interest, but are not validated yet. Catheter related deep vein thrombosis 2411 Table 1 Diagnostic accuracy of Doppler-ultrasound in the diagnosis of upper extremity thrombosis with routine contrast venography as the reference standard Study [reference] Patients (n) CVC (%)* Technique Sensitivity (%) Specificity (%) Manifest/subclinical Prandoni et al. [10] CUS Manifest Prandoni et al. [10] 47 NI Duplex Manifest Prandoni et al. [10] 34 NI CDFI Manifest Baarslag et al. [11] 99 NI CDFI Manifest Baxter et al. [15] CDFI Manifest Ko ksoy et al. [16] CDFI Mixed Haire et al. [17] Duplex Mixed Bonnet et al. [18] Doppler Mixed CUS, compression ultrasound; CDFI, color Doppler flow imaging; NI, not indicated. *Percentage of patients with a central venous catheter (CVC). For definition manifest/subclinical, see text. Incidence and risk factors of CVC-related thrombosis Incidence In numerous studies the incidence of CVC-related thrombosis has been evaluated. In most studies, clinically manifest thrombosis was used as the primary endpoint. Among these studies incidences ranging from 0% to 28% were reported [20,21]. However, the decision to refer for diagnostic imaging upon clinical signs and symptoms for thrombosis lacks uniformity and may be subjective. A more reliable estimate is given by studies in which routine diagnostic screening (ultrasound or venography) was used in consecutive patients with CVCs to determine to assess a diagnosis of thrombosis. For the purpose of this review these studies are selected and summarized in Table 2, according to the indication for the CVC, i.e. the underlying disease and the type of thrombosis (subclinical, clinically manifest and overall) [5,6,8,22 44]. Overall, the reported incidences of CVC-related thrombosis in these studies ranged widely from 2% to 67% (Table 2). The wide range in observed incidence may be partly caused by different diagnostic modalities (venography, ultrasound), the used criteria, and patient- and CVC characteristics. On average, a 30% cumulative incidence can be found in hospitalized patients and the overall majority of thrombotic events remained subclinical [6]. The percentage of clinically manifest thrombosis in these studies ranged from 0% to 12% (Table 2). In some specific populations, such as patients with hemophilia, prospective (screening) studies are not available. In cohort-studies with merely clinical manifest thrombosis as an endpoint incidences ranged from 0% to 3% [45]. Whether in patients with inherited bleeding disorders the risk of thrombosis is reduced as compared with other patients, is not known because of the lack of large studies in which all patients were screened systematically for thrombosis. Risk factors The individual risk of CVC-related thrombosis in a patient is the result of the interaction between patient characteristics, i.e. inherited and acquired risk factors; and the CVC (Fig. 3). There are numerous studies in which risk-factor analysis of CVC-related thrombosis was performed. For inherited and common acquired risk factors cohort studies were considered to represent the highest level of evidence (level 1); case control studies as level 2. For CVC characteristics, randomized trials were considered to represent level 1 of evidence; cohort studies as level 2. Inherited coagulations disorders have been reported to contribute substantially to CVC-related thrombosis in large cohort studies (level 1). Factor V Leiden (FVL) was strongly associated with clinically manifest thrombosis in patients who underwent bone marrow transplantation (n ¼ 277); i.e. 54% of patients with FVL developed thrombosis, in comparison with 10% of patients without (Cox proportional hazard ratio 7.7) [46]. In a large hospital population of 252 patients, the presence of FVL and prothombin G20210A mutation increased the overall risk of CVC-related thrombosis almost threefold [6]. Two other recent performed studies also suggested a contribution of these commonly inherited coagulations disorders [47,48]. In contrast to these studies, a case control study (level 2) reported no increased prevalence of FVL in patients with CVC-related thrombosis as compared with the general western population [49]. In children, similar risk estimates as in adults have been reported. In cohort studies, the risk of thrombosis in FVL carriers in pediatric patients was substantial in patients with acute lymphoid leukemia, as well in mixed populations [43,50,51]. With regard to common acquired risk factors of venous thrombosis there are numerous studies of different level of evidence. In cohort studies, the presence of cancer or active cancer treatment in both, adults and children [6,44], prior thrombo-embolism [32], acquired (temporary) hypercoaguable state [43,52] and a high platelet count at CVC insertion [53] were associated with thrombosis. Age was also associated with CVC-related thrombosis; the risk was higher with increasing age, and in very young children [24,44]. Many CVC characteristics have been associated with an increased risk of CVC-related thrombosis. The type of CVC may be an important factor in the development of CVC-related thrombosis. CVCs composed of silicon or 2412 C. J. van Rooden et al Table 2 Incidence of CVC-related thrombosis amongst studies with routine diagnostic imaging performed in consecutive patients (Doppler-Ultrasound or venography) Study [reference] Population N Technique DVT % (manifest %) Location entry site CVC Chastre et al. [22] ICU 33 V 67 (0) Jugular vein Durbec et al. [23] ICU 70 V 36 (0) Femoral vein Timsit et al. [24] ICU 208 D 33 (0) Subclavian & jugular vein Wu et al. [25] ICU 81 D 56 (0) Jugular vein Joynt et al. [26] ICU 124 D 10 (2) Femoral vein Martin et al. [27] ICU 60 D 58 (2) Axillary vein Stoney et al. [28] Cardiology 203 V 34 (3) Cephalic & jugular vein Goto et al. [30] Cardiology 100 V 23 (0) Cephalic & subclavian vein Lin et al. [29] Cardiology 109 D 6 (0) Cephalic & subclavian vein Antonelli et al. [31] Cardiology 40 V 28 (5) Cephalic & subclavian vein Van Rooden et al. [32] Cardiology 145 D 23 (2) Cephalic & subclavian vein Valerio et al. [33] Oncology 18 V 33 (6) Subclavian vein Brismar et al. [34] Oncology 53 V 36 Subclavian vein Bozetti et al. [35] Oncology 52 V 28 (0) Subclavian vein Haire et al. [5] Haematology 35 V 63 (9) Subclavian vein Balesteri et al. [8] Oncology 57 V 56 (0) Subclavian vein De Cicco et al. [37] Oncology 95 V 66 (6) Subclavian vein Biffi et al. [38] Oncology 302 D 4 (2) Subclavian & cephalic vein Luciani et al. [39] Oncology 145 D 12 (3) Subclavian vein Harter et al. [40] Oncology 233 D 2 (0) Jugular vein Lordick et al. [41] Haematology 43 D 30 (0) Jugular vein Van Rooden et al. [42] Haematology 105 D 28 (12) Jugular & subclavian vein Nowak-Gottl et al. [43] Pediatrics 163 D 11 (11) Subclavian vein Beck et al. [44] Pediatrics 93 D 18 (8) Jugular & subclavian & femoral vein Van Rooden et al. [6] Mixed 252 D 30 (7) Jugular & subclavian vein V, venography; D, Doppler-ultrasound; DVT, deep venous thrombosis. For definition of manifest, see text. 1. Inherited Risk-Factors Factor V Leiden Prothrombin G20210A 2. Acquired Risk-Factors Cancer (treatment) Age Prior DVT Hypercoaguable Thrombosis state 3. Central Vein Catheter Material (PVC) Number of lumina Location tip Vascular trauma Entry-site? Fig. 3. Interaction of inherited, acquired risk-factors of thrombosis with catheter characteristics play an important role the development of central venous catheter-related thrombosis. polyurethane are less often associated with local thrombosis than CVCs made of polyethylene [35,54,36]. In addition, the risk of thrombosis tends to increase with the number of CVC lumina [5,55]. The role of the puncture-site of CVC insertion is still much debated. In two randomized trails (level 1) in intensive care unit patients insertion via the subclavian route had a low risk of thrombosis as compared to a femoral route (0% vs. 25%, respectively 6%) [56,57]. A similar observation was found in a cohort (level 2) study in patients with subclavian vein CVC as compared with jugular CVCs (11% vs. 42%) [24]. In both studies patients were routinely screened by ultrasound for CVC-related thrombosis. However, the Catheter related deep vein thrombosis 2413 methodology of comparing femoral with subclavian vein thrombosis associated with CVCs can be debated as the technique and accuracy of ultrasound in asymptomatic upper and lower DVT differ. In a recent cohort study (level 2) in children, the subclavian route had an increased risk of thrombosis as compared with the jugular route as assessed by a combination of routine venography and routine ultrasound [58]. In cohort studies, a left insertion side has been reported to increase the risk of thrombosis [37,53,58] and with a CVC tip position into the subclavian or innominate vein, thrombosis was more often observed in comparison to a superior caval vein or right atrial tip location [39]. Additional factors in cohort studies that have been reported to increase the risk of thrombosis are a percutaneous insertion procedure, prior CVC at the same puncture site and a prolonged stay of the CVC for over 2 weeks [58,59]. Summary In summary, CVC-related thrombosis is a multicausal disease. Prothrombotic factors (e.g. FVL) and the underlying disease (cancer) may play an important role in the development of CVC-related thrombosis. Some important CVC characteristics increase the risk of thrombosis, such as the type and material of the CVC, vascular trauma and the duration of stay of the CVC. Complications Catheter related thrombosis may be associated with several complications including PE, infection of the thrombus, CVC dysfunction and subsequent loss of intravenous access and post-thrombotic syndrome or recurrent thrombosis. Pulmonary embolism The reported incidence of PE as a complication of catheterrelated thrombosis varies. In only one study, all patients with proven thrombosis systematically underwent screening for PE (ventilation-perfusion scan) and a 15% cumulative incidence was reported [60]. In other studies incidences of PE, using merely clinical endpoints, varied greatly. Whereas incidences of symptomatic PE up to 17% have been reported, others did not observe any PE [61,62]. PE associated with CVC-related thrombosis has been reported to be the cause of death [7,60]. Screening for PE if a diagnosis of CVC-related thrombosis is established is usually not mandatory, as in most patients anticoagulant treatment is initiated, eventually with a removal of the CVC. A firm evidence regarding clinical outcome needs however to be established prospectively. Infection The CVC-related thrombosis and CVC-related infection have been reported to be associated [24,41,63,64]. The pathogenesis of catheter-related infection seems to depend on the development of thrombosis of the catheter. Several thromboproteins were shown to increase the risk of subsequent infection [65,66]. Results from a postmortem study in 72 patients with a CV
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks